Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical results from its ongoing Phase 1 investigational trial (NCT06408311) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback